According to investigators, a key reason for the link may lie in circadian “clocks,” the molecular machinery within every cell of every organism, which have evolved to adapt to daily stresses, such as changes in light and temperature caused by the rising and setting of the sun.
Minute movements are related to patching treatment outcomes in patients.
Increasing understanding of the genetics behind Usher syndrome suggests that treatment may become possible in the very near future.
Retina specialists and their patients have learned how AI and telemedicine can be effective in monitoring disease progression and alerting clinicians to early signs of adverse changes.
Biologic treatments can be utilised to help the eye heal itself in inflammatory conditions such as dry eye disorder.
According to Novartis, the approval is based on year 1 data from the Phase III KESTREL and KITE clinical trials investigating brolucizumab-dbll 6 mg vs aflibercept 2 mg in diabetic macular oedema patients.
It is important to select good candidates for presbyopia-correcting IOL implantation and frankly discuss postoperative adjustment issues for a successful outcome.
Each new generation of cyclophotocoagulation options results in more accurate visualisation of the ciliary processes, greater ease of use and fewer complications.
Eye rubbing is an essential factor in the development of keratoconus. “No rub, no cone” is the rule: a genetic predisposition for the disease will come to nothing without excessive eye rubbing.
In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment. Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.
Physicians offer pearls for improving visualisation in eyes using retroillumination techniques.
Practice makes perfect when adopting this method for intrascleral IOL fixation.
An investigator at Anglia Ruskin University is leading work on an anti-cataract drug, which has had positive results in lab tests.
BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).
Polarisation-sensitive optical coherence tomography has facilitated early diagnosis of disease before it becomes apparent on topography.
Promising gene therapies in development are pinpointing steps in the pathogenic cascades involved in ocular diseases, such as VEGF for wet AMD and CFI for dry AMD.
An ischaemia modulator has demonstrated it is safe and well tolerated in a Phase 1/2a trial in diabetic macular ischaemia patients.
Patients are at risk for developing severe dry eye and ocular surface disease.
With minimally invasive surgery procedures becoming increasingly popular in glaucoma management, canaloplasty using an ab-interno surgical technique offers enhanced natural aqueous outflow in open-angle glaucoma.
Dr Goes reflects on a life at the forefront of ophthalmology, considering advancements in technology and the knowledge that has changed his practice and improved outcomes for patients.
TP-03 met the primary and all secondary endpoints, effectively resolved Demodex blepharitis and was well-tolerated with no serious treatment-related adverse events. 56% of patients on TP-03 achieved the primary endpoint of complete collarette cure.
In research sponsored by Skye Bioscience Inc., investigators at the University of Mississippi have demonstrated stronger and longer-lasting reduction of intraocular pressure when a proprietary molecule, SBI-100, is formulated as a nanoemulsion containing the mucoadhesive agent Carbopol 940.
Dr Eva Chamorro points out that myopia control spectacle lenses affect the diurnal rhythms in the AL in young adult human and produced a small short-term increase in the AL that varies in intensity and time interval for each of the 3 studied lenses.
Investigators from the Karolinska Institutet and St. Erik Eye Hospital, Stockholm, Sweden, reported that they have developed a prognostic test, referred to as serUM, that they believe is a strong predictor of metastasis of uveal melanoma.
THR-687 is currently being evaluated in a phase 2 clinical trial in patients with DME. The first data from the dose-optimization study is expected to be released in the first half of 2022.
The study found no association between treatment and the risk of chronic kidney disease or end-stage renal disease.
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Dr Osama Ibrahim Hirayama and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.
During a presentation at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting, Dr Yuichi Hori and colleagues found that taping the top border of a surgical mask to a clinicians’ skin reduces the potential for ocular surface damage resulting from expirations of air reaching the ocular surface during the COVID-19 pandemic.
